L'ASSOCIATION ENTRE L'HALOPERIDOL ET L'ORPHENADRINE DANS LA THERAPIE DE LA SCHIZOPHRENIE: UNE ETUDE CLINIQUE ET PHARMACOCINETIQUE

A. C. Altamura, M. Buccio, G. Colombo, A. Terzi, C. L. Cazzullo

Research output: Contribution to journalArticlepeer-review

Abstract

The use of anti-cholinergic drugs for counteracting neuroleptic induced extrapyramidal side-effects (EPS) is controversial. A possible increase in anticholinergic symptoms and a pharmacokinetic interaction are reported in literature. In order to determine these points, 22 schizophrenic patients were studied. Haloperidol (HL) was administered for 3 weeks and Orphenadrine (ORD) only in the second week of treatment. ORD reduced significantly EPS and its withdrawal led to a marked deterioration of EPS and the psychopathological picture. There was an increase in HL plasma levels after starting ORD, and ORD plasma levels were positively related to EPS amelioration. Finally, prolactin seemed to be higher in those patients with EPS, particularly after ORD withdrawal.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalEncephale
Volume12
Issue number1
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'L'ASSOCIATION ENTRE L'HALOPERIDOL ET L'ORPHENADRINE DANS LA THERAPIE DE LA SCHIZOPHRENIE: UNE ETUDE CLINIQUE ET PHARMACOCINETIQUE'. Together they form a unique fingerprint.

Cite this